Tissue engineering is a scientific field majorly focused on the development of tissue and organ substitutes by controlling biophysical, biological, and/or biomechanical parameters in the laboratory. Tissue engineering has emerged as a rapidly expanding approach to address shortage of organs in transplantation procedures and is a major component of regenerative medicine. The general principles of tissue engineering involve combining living cells with a synthetic or natural support or scaffold to build a three dimensional living construct that is structurally, functionally, and mechanically equal to or better than the tissue that is to be replaced. The primary goal of tissue engineering is to activate the body's lost regenerative abilities and, if necessary, to replace damaged tissue with tissue implants. Due to the particular technical difficulties, the generation of tissue constructs requires particularly close collaboration by physicians, cell biologists, materials scientists and engineers. The main goal of tissue engineering is the development of functional substitutes for damaged tissue. It is estimated that the majority of tissue engineering products are used to treat injuries and congenital defects, while tissue engineering products are less commonly used to treat disease.
Market Dynamics
Increasing adoption of inorganic growth strategies by key players in market such as acquisitions is expected to drive market growth over the forecast period. For instance, in October 2021 3D Systems, an engineering company provides comprehensive products and services, including 3D printers, print materials, software, on-demand manufacturing services, announced the acquisition of Volumetric Biotechnologies, a Houston-based biotech company. Volumetric’s mission is to develop the ability to manufacture human organs using bioprinting methods. Through this acquisition, 3D Systems plans to establish a world-class research capability in Houston, Texas, related to life sciences.
Key features of the study:
- This report provides an in-depth analysis of the global tissue engineering market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global tissue engineering market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Acelity L.P. Inc., Allergan Plc., Athersys, Inc., B. Braun, BioMimetic Therapeutics, Bio Tissue Technologies, C. R. Bard, International Stem Cell, Integra Lifesciences, Medtronic, Inc., Organogenesis Inc., Osiris Therapeutics, RTI surgical, Inc., Stryker Corporation, Tissue Regenix Group Plc., and Zimmer Biomet.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global tissue engineering market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global tissue engineering market
Detailed Segmentation:
- Global Tissue Engineering Market, By Material Type:
- Synthetic
- Biological
- Others
- Global Tissue Engineering Market, By Application:
- Dermal
- Orthopedic
- Dental
- Neurology
- Others
- Global Tissue Engineering Market, By Region:
- North America
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Region/Country
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Acelity L.P. Inc.
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Allergan Plc
- Athersys, Inc.
- Braun
- BioMimetic Therapeutics
- Bio Tissue Technologies
- R. Bard
- International Stem Cell
- Integra Lifesciences
- Medtronic
- Organogenesis Inc.
- Osiris Therapeutics
- RTI surgical, Inc.
- Stryker Corporation
- Tissue Regenix Group Plc.
- Zimmer Biomet.
“*” marked represents similar segmentation in other categories in the respective section.